268 related articles for article (PubMed ID: 17983387)
1. Oral reactions to sublingual immunotherapy: a bioptic study.
Marcucci F; Sensi L; Incorvaia C; Di Cara G; Moingeon P; Frati F
Allergy; 2007 Dec; 62(12):1475-7. PubMed ID: 17983387
[No Abstract] [Full Text] [Related]
2. Clinical trial shows sublingual immunotherapy to be effective for treatment of children with grass pollen allergy.
Wilkinson J
Immunotherapy; 2012 Nov; 4(11):1091-2. PubMed ID: 23194357
[No Abstract] [Full Text] [Related]
3. Sublingual immunotherapy.
Frew AJ
N Engl J Med; 2008 May; 358(21):2259-64. PubMed ID: 18499568
[No Abstract] [Full Text] [Related]
4. Simultaneous SCIT with 2 separate allergen extracts demonstrates comparable safety compared to SCIT with a single allergen extract.
Röder A; Darrelmann N; Klingenberg W; Krüll M; Suttorp N; Noga O
J Investig Allergol Clin Immunol; 2009; 19(6):512-3. PubMed ID: 20128433
[No Abstract] [Full Text] [Related]
5. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
6. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile.
Calderón MA; Simons FE; Malling HJ; Lockey RF; Moingeon P; Demoly P
Allergy; 2012 Mar; 67(3):302-11. PubMed ID: 22150126
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and its persistence, in children and adults.
Di Rienzo V
Int J Immunopathol Pharmacol; 2005; 18(4 Suppl):35-7. PubMed ID: 17761106
[No Abstract] [Full Text] [Related]
8. Susceptibility of a grass-pollen oral immunotherapy extract to the saliva and gastric fluid digestive process.
Igea JM; Cuevas M; Lázaro M; Quirce S; Cuesta J
Allergol Immunopathol (Madr); 1994; 22(2):55-9. PubMed ID: 8059676
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
10. Anaphylaxis caused by allergen sublingual immunotherapy?
André C; Fadel R
Allergy; 2007 Oct; 62(10):1220-1. PubMed ID: 17845597
[No Abstract] [Full Text] [Related]
11. Sublingual immunotherapy: focus on tablets.
Passalacqua G; Canonica GW
Ann Allergy Asthma Immunol; 2015 Jul; 115(1):4-9. PubMed ID: 26123419
[No Abstract] [Full Text] [Related]
12. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?
Allam JP; Stojanovski G; Friedrichs N; Peng W; Bieber T; Wenzel J; Novak N
Allergy; 2008 Jun; 63(6):720-7. PubMed ID: 18445186
[TBL] [Abstract][Full Text] [Related]
13. Update on sublingual immunotherapy treatment regimes.
Spangfort MD
Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):244. PubMed ID: 17124783
[No Abstract] [Full Text] [Related]
14. [The mechanisms of allergen-specific immunotherapy more clear].
Rak S
Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1935-7. PubMed ID: 18681375
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
Stelmach I; Kaczmarek-Woźniak J; Majak P; Olszowiec-Chlebna M; Jerzynska J
Clin Exp Allergy; 2009 Mar; 39(3):401-8. PubMed ID: 19134016
[TBL] [Abstract][Full Text] [Related]
16. LAIS - Posological schedules.
Bruno M
Int J Immunopathol Pharmacol; 2005; 18(4 Suppl):33-4. PubMed ID: 17761105
[No Abstract] [Full Text] [Related]
17. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
[TBL] [Abstract][Full Text] [Related]
18. The biological potency of different extracts for sublingual immunotherapy assessed by skin prick tests.
Rossi R; Monasterolo G; Passalacqua G
Eur Ann Allergy Clin Immunol; 2010 Jun; 42(3):112-4. PubMed ID: 20648773
[TBL] [Abstract][Full Text] [Related]
19. Survey on the safety of a no-updosing regimen of sublingual immunotherapy.
Musarra A; Cilia M; Pecora S; Passalacqua G
Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):313-4. PubMed ID: 17191752
[No Abstract] [Full Text] [Related]
20. Grazax sublingual immunotherapy in pre-co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy?
Nakonechna A; Hills J; Moor J; Dore P; Abuzakouk M
Ann Allergy Asthma Immunol; 2015 Jan; 114(1):73-4. PubMed ID: 25457868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
